Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call By: Ironwood Pharmaceuticals, Inc. via Business Wire April 22, 2021 at 16:01 PM EDT Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 6, 2021. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) using conference ID number and event passcode 8067476. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting Thursday, May 6, 2021 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on May 20, 2021. To listen to the replay, dial (800) 585-8367 (U.S. and Canada) or (416) 621-4642 (international) using conference ID number 8067476. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations. View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005103/en/Contacts Media and Investors: Meredith Kaya, 617-374-5082 Vice President, Finance and Investor Relations mkaya@ironwoodpharma.com Investors: Matt Roache, 617-621-8395 Director, Investor Relations mroache@ironwoodpharma.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call By: Ironwood Pharmaceuticals, Inc. via Business Wire April 22, 2021 at 16:01 PM EDT Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 6, 2021. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) using conference ID number and event passcode 8067476. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting Thursday, May 6, 2021 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on May 20, 2021. To listen to the replay, dial (800) 585-8367 (U.S. and Canada) or (416) 621-4642 (international) using conference ID number 8067476. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations. View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005103/en/Contacts Media and Investors: Meredith Kaya, 617-374-5082 Vice President, Finance and Investor Relations mkaya@ironwoodpharma.com Investors: Matt Roache, 617-621-8395 Director, Investor Relations mroache@ironwoodpharma.com
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 6, 2021. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) using conference ID number and event passcode 8067476. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting Thursday, May 6, 2021 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on May 20, 2021. To listen to the replay, dial (800) 585-8367 (U.S. and Canada) or (416) 621-4642 (international) using conference ID number 8067476. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations. View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005103/en/
Media and Investors: Meredith Kaya, 617-374-5082 Vice President, Finance and Investor Relations mkaya@ironwoodpharma.com Investors: Matt Roache, 617-621-8395 Director, Investor Relations mroache@ironwoodpharma.com